新的治疗方案，通过向患者自动注射G-Lasta®来减轻化疗患者的就诊负担
2022年12月6日，Kyowa Kirin Co宣布，G-Lasta®皮下注射3.6mg自动注射设备[pegfilgrastim（基因重组），长效粒细胞集落刺激因子1（G-CSF）制剂]在日本推出，以降低接受癌症化疗患者中性粒细胞减少症的发病率。
G-Lasta®是一种长效G-CSF制剂，已由Amgen K-a，Inc.授权给Kyowa Kirin。自2014年以来，该药在日本上市，有降低接受癌症化疗患者中性粒细胞减少症发热发病率的迹象。它通常由医护人员在化疗后至少一天服用。这种自动注射装置的工作原理是在将G-Lasta®注射到患者身上约27小时后将其注射到体内。通过在化疗当天将其贴在患者身上，可以省去第二天服用G-Lasta®所需的额外门诊就诊。Kyowa Kirin认为，该产品可以减轻化疗患者的负担。
完整资料附件：https://www.info.pmda.go.jp/go/pack/3399410G1020_1_06/
----------------------------------------
G-LASTA Subcutaneous Injection 3.6mg（Pegfilgrastim[Genetical recombination]）
Brand name :G-LASTA Subcutaneous Injection 3.6mg
Active ingredient:Pegfilgrastim(Genetical recombination)
Dosage form:
injection
Print on wrapping:
Effects of this medicine
This medicine increases leukocytes (neutrophils) which play an important role for protection against infection.
It is usually used to treat leukopenia (neutropenia) attributed to anticancer agents.
Before using this medicine, be sure to tell your doctor and pharmacist
If you have previously experienced any allergic reactions(itch, rash, etc.)to any medicines.
If you have previously experienced rash or itch after administrating any other medicines which increases leukocytes (neutrophils).
If you have myeloid leukemia(including myelodysplastic syndrome)with insufficient decrease of leukemic cells in the bone marrow or presence of leukemic cells in the blood.
If you have been administered an anticancer agent within 24 hours.
If you are pregnant or breastfeeding.
If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
Dosing schedule (How to take this medicine)
Your dosing schedule prescribed by your doctor is ((to be written by a healthcare professional))
In general, this medicine is administered subcutaneously once per chemotherapy course, on or after the next day of treatment completion with anticancer agent.
Duration of administration will be determined by monitoring the effects. Ask your doctor about the duration of administration.
Precautions while taking this medicine
Possible adverse reactions to this medicine
The most commonly reported adverse reactions include back pain, fever, arthralgia, malaise, headache, muscle pain and rash. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
chilliness, palpitation, cold sweat, grow pale[shock, anaphylaxis]
fever, dry cough, difficult to breathe[interstitial lung disease]
hard to breathe, rapid breathing, lips turn blue, nails and toenails turn blue [acute respiratory distress syndrome]
shortness of breath, fever, general malaise, easy to bleed, dizziness[increase of blasts]
left upper quadrant pain, shoulder pain, abdominal bloating [splenomegaly, splenic rupture]
hypotension, edema, rapid weight increase[capillary leak syndrome]
fever, raised red rash with pain[Sweet's syndrome]
fever, bruise, blood blister[cutaneous vasculitis]
fever, general malaise, headache, dizziness[large vessel vasculitis(inflammation of aorta, common carotid artery, subclavian artery, etc)]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
Injection
Revised: 6/2018
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment. |
